Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Stopped early · Phase 2
Conditions studied: Hodgkin Disease
In brief
Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine. The introduction of these new agents with their different mechanisms of action into the Stanford V regimen may increase effectiveness while maintaining a favorable toxicity profile with respect to fertility and a low risk of secondary leukemia. On this basis, we propose a new regimen, Stanford VI, for patients with bulky and advanced HD with 3 or more risk factors.
Key facts
- Study ID
- NCT00225173
- Run by
- Stanford University
- People needed
- 45
- Starts
- 2001-10-01
- Expected to finish
- 2006-09-01
- Last updated by the study team
- 2014-08-27
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Untreated, locally extensive or advanced stage classical Hodgkin's disease
- 3 or more adverse risk factors
- Age > 18 years and < 70 years.
- No prior invasive malignancies for > 5 years except curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- ECOG performance status 0 to 2
- WBC > 4000/µL
- Platelets > 100,000/µL
- Creatinine < 2.0mg/dL
- Bilirubin < 5.0mg/dL
You may not qualify if…
- HIV-positive
- Pregnant or currently breast feeding women
- Lymphocyte predominant Hodgkin's disease
Where it is running
- Stanford University Medical Center — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.